Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response

NCT02955758 is registered in ClinicalTrials.gov with Joel Neal as lead sponsor.

NCT NCT02955758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response
Lead sponsor
Joel Neal
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
April 9, 2024
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-squamous non-small cell lung carcinoma